Latest News
See all →ITM to Announce Phase 3 COMPETE Trial Post Hoc Subgroup Analyses and Host Satellite Symposium at NANETS 2025
Garching / Munich, Germany, October 17, 2025 -ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced…
Read moreITM Appoints Annette Breunig as Chief People Officer
- Global HR leader to drive ITM’s long-term human resources strategy, support organizational development and corporate growth
Garching / Munich,…
Read moreITM Presents Dosimetry Data from Phase 3 COMPETE Trial Supporting Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors at EANM 2025 Annual Congress
- Study showed targeted tumor uptake with low healthy organ exposure in broad cohort of 207 patients
- Supports therapeutic potential of ITM’s proprietary…
